Previous 10 | Next 10 |
home / stock / invvy / invvy news
SLOUGH, United Kingdom and RICHMOND, Va. , April 9, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) issued the following statement today in response to an indictment returned by a federal grand jury in the Western District of Virginia : "We are extremely disappointed in thi...
SLOUGH, England and RICHMOND, Va., April 6, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced data from two new studies: the first provides insights into dosing of once-monthly SUBLOCADE™ (buprenorphine extended-release) injection for subcutaneous use (CIII) fo...
Results from a Phase 3 clinical trial, RECOVER, evaluating Indivior PLC's ( OTCPK:INVVY ) SUBLOCADE (buprenorphine extended-release), administered via subcutaneous injection once per month, in patients with severe opioid use disorder (OUD) showed a sustained treatment benefit. The data we...
SLOUGH, England and RICHMOND, Va. , April 5, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced data from two studies evaluating efficacy and long-term safety of once-monthly SUBLOCADE™ (buprenorphine extended-release) injection for subcutaneous use (CIII) for the t...
SLOUGH, England and RICHMOND, Va. , March 7, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of patient-centered outcome endpoints (health status, physical and mental health, medication satisfaction, employment, health insurance status and healthcar...
SLOUGH, England and RICHMOND, Va. , Feb. 27, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the launch of once-monthly PERSERIS ™ (risperidone) for extended-release injectable suspension in the United States . PERSERIS is approved by the U.S. Food and Dru...
SLOUGH, England and RICHMOND, Va. , Feb. 20, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its U.S. affiliate, Indivior Inc., has launched an authorized generic version of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. The a...
SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 19, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that data from its pivotal phase 3 clinical trial evaluating the efficacy, safety and tolerability of SUBLOCADE TM (buprenorphine extended-release) injection for subcu...
Indivior PLC (INVVY) Q4 2018 Earnings Conference Call February 14, 2019 06:30 AM ET Company Participants Shaun Thaxter - CEO Mark Crossley - CFO Javier Rodriguez - Chief Legal Officer Christian Heidbreder - Chief Scientific Officer Conference Call Participants Graham Parr...
The following slide deck was published by INDIVIOR PLC ADR in conjunction with their 2018 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
Indivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance PR Newswire RICHMOND, Va. , May 23, 2024 /PRNewswire/ -- Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation o...
Indivior Announces Q1 2024 Financial Results PR Newswire SLOUGH, United Kingdom and RICHMOND, Va. , April 25, 2024 /PRNewswire/ -- Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024 . The earnings re...
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone PR Newswire This head-to-head pharmacodynamic study in healthy volunteers...